Payment overview · 2025
General Payments
$916.23
44 reported records · 16 companies
Healthcare provider profile · identity verified
Robert Ryan Johnson, DO
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, KY · NPI 1790796654
Verified facts
What the public records show
CMS Open Payments records show Robert Ryan Johnson, DO received $916.23 in general payments during 2025 across 44 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $267.90 | 29.2% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $180.55 | 19.7% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $102.00 | 11.1% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.47 | 7.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.52 | 4.8% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.55 | 4.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.52 | 3.4% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.56 | 3.1% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $26.35 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.11 | 2.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.06 | 2.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.82 | 2.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.89 | 2.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.29 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.71 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.93 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $916.23 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $239.15 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $182.75 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $181.58 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.84 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $98.84 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $77.47 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.05 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.05 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.47 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.47 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.09 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $39.55 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $39.55 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $28.56 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 147 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 120 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 151 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 193 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 28 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
147 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 25 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
151 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
193 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
164 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 780 | 232 |
| Levothyroxine Sodium | Levothyroxine Sodium | 585 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 479 | 145 |
| Lisinopril | Lisinopril | 459 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 457 | 139 |
| Omeprazole | Omeprazole | 375 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 366 | 109 |
| Gabapentin | Gabapentin | 329 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 325 | 93 |
| Metformin Hcl Er | Metformin Hcl | 292 | 81 |
| Potassium Chloride | Potassium Chloride | 292 | 86 |
| Furosemide | Furosemide | 270 | 89 |
| Trazodone Hcl | Trazodone Hcl | 243 | 69 |
| Losartan Potassium | Losartan Potassium | 242 | 68 |
| Bupropion Xl | Bupropion Hcl | 228 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 214 | 68 |
| Methylprednisolone | Methylprednisolone | 207 | 140 |
| Montelukast Sodium | Montelukast Sodium | 207 | 55 |
| Buspirone Hcl | Buspirone Hcl | 204 | 61 |
| Allopurinol | Allopurinol | 202 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 199 | 52 |
| Ozempic | Semaglutide | 193 | 41 |
| Metformin Hcl | Metformin Hcl | 183 | 55 |
| Simvastatin | Simvastatin | 177 | 51 |
| Sertraline Hcl | Sertraline Hcl | 170 | 51 |
| Eliquis | Apixaban | 164 | 38 |
| Alendronate Sodium | Alendronate Sodium | 163 | 47 |
| Ezetimibe | Ezetimibe | 162 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 57 |
| Mounjaro | Tirzepatide | 151 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 53 |
| Glipizide | Glipizide | 150 | 40 |
| Mirtazapine | Mirtazapine | 149 | 43 |
| Farxiga | Dapagliflozin Propanediol | 147 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 35 |
| Pregabalin | Pregabalin | 142 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 137 | 102 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 133 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 132 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 132 | 42 |
| Famotidine | Famotidine | 125 | 45 |
| Jardiance | Empagliflozin | 120 | 25 |
| Warfarin Sodium | Warfarin Sodium | 116 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 48 |
| Meloxicam | Meloxicam | 113 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 111 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 30 |
| Ondansetron Odt | Ondansetron | 107 | 52 |
| Carvedilol | Carvedilol | 105 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 102 | 28 |
| Lorazepam | Lorazepam | 99 | 15 |
| Tramadol Hcl | Tramadol Hcl | 99 | 23 |
| Alprazolam | Alprazolam | 97 | 15 |
| Cephalexin | Cephalexin | 95 | 56 |
| Azithromycin | Azithromycin | 85 | 63 |
| Amitriptyline Hcl | Amitriptyline Hcl | 84 | 23 |
| Synthroid | Levothyroxine Sodium | 83 | 20 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 81 | 24 |
| Amoxicillin | Amoxicillin | 80 | 58 |
| Baclofen | Baclofen | 80 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 21 |
| Topiramate | Topiramate | 76 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 69 | 13 |
| Naltrexone Hcl | Naltrexone Hcl | 68 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 15 |
| Xarelto | Rivaroxaban | 66 | 18 |
| Donepezil Hcl | Donepezil Hcl | 65 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 62 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 17 |
| Trulicity | Dulaglutide | 60 | 14 |
| Valsartan | Valsartan | 60 | 19 |
| Spironolactone | Spironolactone | 59 | 17 |
| Celecoxib | Celecoxib | 58 | 14 |
| Mupirocin | Mupirocin | 58 | 40 |
| Clonazepam | Clonazepam | 57 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 28 |
| Linzess | Linaclotide | 55 | 19 |
| Promethazine Hcl | Promethazine Hcl | 55 | 14 |
| Meclizine Hcl | Meclizine Hcl | 51 | 19 |
| Prednisone | Prednisone | 50 | 38 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 49 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 20 |
| Lansoprazole | Lansoprazole | 46 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 13 |
| Ibuprofen | Ibuprofen | 45 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 11 |
| Januvia | Sitagliptin Phosphate | 43 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 17 |
| Chlorthalidone | Chlorthalidone | 42 | 14 |
| Glipizide Er | Glipizide | 42 | 12 |
| Vilazodone Hcl | Vilazodone Hcl | 42 | suppressed |
| Atenolol | Atenolol | 40 | 13 |
| Benazepril Hcl | Benazepril Hcl | 40 | 11 |
| Colestipol Hcl | Colestipol Hcl | 38 | 14 |
| Fluconazole | Fluconazole | 38 | 32 |
| Lidocaine | Lidocaine | 38 | 14 |
| Valacyclovir | Valacyclovir Hcl | 38 | 21 |
| Klor-Con M20 | Potassium Chloride | 36 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 13 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 11 |
| Lamotrigine | Lamotrigine | 31 | 14 |
| Naproxen | Naproxen | 30 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | 11 |
| Nystatin | Nystatin | 29 | 21 |
| Temazepam | Temazepam | 29 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 21 |
| Cilostazol | Cilostazol | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 12 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 11 |
| Clotrimazole | Clotrimazole | 17 | 13 |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Tadalafil | Tadalafil | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Oxaprozin | Oxaprozin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Zocor | Simvastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $916.23 · 44 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, FANAPT, FARXIGA, GARDASIL 9, HETLIOZ, JARDIANCE, JOURNAVX, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, SPRAVATO, UBRELVY, VOQUEZNA, Veozah, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error